Moexipril

Angiotensin Converting Enzyme Inhibitor — CARDIOVASCULAR SYSTEM

Key facts

Moexipril is an ofp drug in the Angiotensin Converting Enzyme Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1995. Its mechanism of action is classified as Angiotensin-converting Enzyme Inhibitors. DrugCentral lists 1 molecular target, including ACE. Recorded indications include Hypertensive disorder.

• Approval status: ofp (first approved 1995 by the FDA).
• Drug class: Angiotensin Converting Enzyme Inhibitor.
• Mechanism of action: Angiotensin-converting Enzyme Inhibitors.
• Molecular targets: ACE (1 listed in DrugCentral).
• Indications: Hypertensive disorder.
• ATC code: C09AA13 (ACE inhibitors, plain).
• Molecular formula: C27H34N2O7; molecular weight 498.58 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hypertensive disorder

Off-label uses (5)

• Atrial fibrillation
• Chronic heart failure
• Diabetic renal disease
• Diastolic heart failure
• Nondiabetic Proteinuric Nephropathy

Contraindications (39)

• Acute cerebrovascular insufficiency
• Acute pancreatitis
• Acute vomiting
• Angioedema
• Anuria
• Aortic valve stenosis
• Azotemia
• Bone marrow depression
• Dehydration
• Diabetes mellitus
• Disease of liver
• Disorder of connective tissue
• Gout
• Hemodialysis with High-Flux Membrane
• Hepatic coma
• Hypercalcemia
• Hypercholesterolemia
• Hyperkalemia
• Hyperparathyroidism
• Hyperuricemia
• Hypochloremic alkalosis
• Hypokalemia
• Hypomagnesemia
• Hyponatremia
• Hypovolemia
• Intestinal Angioedema
• Jaundice
• Kidney disease
• Liver function tests abnormal
• Low blood pressure
• + 9 more

Mechanism & targets

• Mechanism of action (MoA): Angiotensin-converting Enzyme Inhibitors
• Established pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Angiotensin-converting enzyme	ACE	inhibitor	IC50 8.59

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1995-04-19	FDA	—	UCB INC

ATC classification

ATC code	Therapeutic hierarchy
C09AA13	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, PLAIN › ACE inhibitors, plain
C09BA13	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors and diuretics

Chemical structure

• Molecular formula: C₂₇H₃₄N₂O₇
• Molecular weight: 498.58 g/mol
• CAS number: —
• InChIKey: UWWDHYUMIORJTA-HSQYWUDLSA-N
• PubChem CID: 55331

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Moexipril used for?

DrugCentral lists the following indications for Moexipril: Hypertensive disorder.

How does Moexipril work?

Moexipril is classified as Angiotensin-converting Enzyme Inhibitors; its molecular targets in DrugCentral include ACE (inhibitor).

When was Moexipril first approved?

Moexipril was first approved by the FDA in 1995.

What drug class does Moexipril belong to?

Moexipril is in the Angiotensin Converting Enzyme Inhibitor class.

What is the chemical formula of Moexipril?

Moexipril has the molecular formula C27H34N2O7 and a molecular weight of 498.58 g/mol.

Sources

• DrugCentral drug card 1827 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1165 — compound record and bioactivity
• PubChem CID 55331 — chemical identifiers
• DrugBank DB00691 — drug record
• FDA UNII H3753190JS — substance identity
• DailyMed: FDA labels for Moexipril — current prescribing information (label search)
• UniProt P12821 (ACE) — target protein

How this page is built: methodology · editorial policy & corrections.